DexCom, Inc. (DXCM:NASDAQ) closed at $82.29 on October 30, 2026, up 2.95% on the day. The stock trades 11.1% below its 52-week high of $92.59 and 52.1% above its 52-week low of $54.11. Over the past year, it gained 41.3%. DexCom, Inc. is part of the Health Care sector (Medical/Dental Instruments).
In 252 trading sessions since October 30, 2025, DXCM closed higher on 128 days (51%). Its best day was July 31, 2026 (+11.95%) and its worst was October 31, 2025 (-14.63%). The stock moved 10% or more in a single session 2 times. It opened at least 5% above the previous day's high 1 time.
DexCom, Inc., a medical device company, together with its subsidiaries, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers in the hospital for the treatment of patients with and without diabetes. Its products include DexCom G4 PLATINUM system for continuous use by adults with diabetes; DexCom G4 PLATINUM with Share, a remote monitoring system; and DexCom G5 Mobile, a CGM system that directly communicates to a patient's mobile and its data can be integrated with DexCom CLARITY, which is a next generation cloud-based reporting software for personalized, easy-to-understand analysis of trends to improve diabetes management. The company also offers sensor augmented insulin pumps. It has a collaboration and license agreement with Verily Life Sciences LLC to develop a series of next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. The company was founded in 1999 and is headquartered in San Diego, California.
Find more stocks like DXCM with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.